This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Findings Show Treating Gum Disease Can Lower Pharmacy Costs For People With Diabetes

HARRISBURG, Pa., Nov. 14, 2012 /PRNewswire/ -- New findings from an oral health study conducted earlier this year by United Concordia Dental and Highmark Inc. show pharmacy costs can average $1,477 lower per year for diabetics who have gum disease and receive at least seven treatments or visits to treat the disease.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/58161-highmark-united-concordia-dental-gum-disease-pharmacy-costs-diabetes  

(Photo: http://photos.prnewswire.com/prnh/20121114/MM11652 )

"We previously reported that periodontal treatment for individuals with diabetes was associated with a significant decrease in hospitalizations and doctor visits, delivering annual savings of $1,814 in medical care per patient per year, independent of age and sex," said lead researcher Marjorie Jeffcoat, D.M.D., professor and dean emeritus of the University of Pennsylvania School of Dental Medicine. "We are excited to now know that continued periodontal therapy decreases outpatient drug costs."

Earlier this year, the nation's sixth largest dental insurer unveiled significant findings related to annual medical savings, hospitalizations and doctor visits from its landmark study of 1.7 million patients. Dr. Jeffcoat used the same group of patients, who have both United Concordia dental and Highmark medical coverage, to conduct the pharmacy cost savings analysis.

"United Concordia's oral health study – the largest of its kind – delivers a strong message: annual heath care savings of more than $3,200 are possible, when you combine the medical and pharmacy savings for individuals with diabetes who are treated for gum disease and have at least seven visits as part of their therapy," said James Bramson, D.D.S., chief dental officer, United Concordia Dental. "Clearly, these findings help broaden the argument for why it makes sense for employers to invest in robust chronic-disease specific oral health programs.  We are currently working with medical carriers and wellness companies to integrate the oral health component into employers' benefit and wellness programs." The diabetes findings represent the first in a series of conclusions suggesting how appropriate dental treatment and maintenance can help predict lower medical expenses for various chronic medical conditions. Similar methodologies will be employed to examine cost impact of treating periodontal disease in individuals who experienced pre-term births, heart disease and stroke.

"This study and its findings are consistent with an emerging body of evidence associating gingivitis, type 2 diabetes and vascular disease," said Dr. Anthony J. Cannon, endocrinologist; regional board president of the Greater Philadelphia, Central Pennsylvania and Southern New Jersey regions of the American Diabetes Association (ADA); and member of the National African American Initiative Committee of the ADA.  "This research clearly shows individuals with diabetes can benefit in the form of reduced medical and drug costs and fewer hospitalizations and doctor visits by managing their oral health."

To learn more about the UCWellness program and the connection between diabetes and oral health, visit www.UnitedConcordia.com.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs